Real-world Study of Taletrectinib for Advanced ROS1+ NSCLC With Brain Metastases

RecruitingOBSERVATIONAL

Enrollment

100

Participants

Timeline

Start Date

June 4, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

December 31, 2027

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG

Taletrectinib

Taletrectinib, 600mg, QD

Trial Locations (1)

RECRUITING

Zhejiang Cancer Hospital, Hangzhou

All Listed Sponsors

lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

NCT07008287 - Real-world Study of Taletrectinib for Advanced ROS1+ NSCLC With Brain Metastases | Biotech Hunter | Biotech Hunter